Search tips
Search criteria 


Logo of jresmedsciCurrent issueInstructionsSubmit articleJournal of Research in Medical Sciences
J Res Med Sci. 2013 July; 18(7): 561–566.
PMCID: PMC3897022

Atypical antipsychotic use is an independent predictor for the increased mean platelet volume in patients with schizophrenia: A preliminary study



Cardiovascular diseases, cardiovascular risk factors, and mortality due to these situations are more frequently encountered in schizophrenic patients when compared with the general population. The mean platelet volume (MPV) is a surrogate biomarker of the platelet activity and an useful prognostic test in cardiometabolic diseases. The aim of this study was to investigate what influenced MPV levels in patients with schizophrenia.

Materials and Methods:

We evaluated hospital records of 60 hospitalized schizophrenia patients. Thirty age- and sex-matched healthy control subjects were also included as a control group.


MPV levels were significantly higher in patients who were on atypical antipsychotic drugs than in patients who were not using any drug (9.2 ± 0.8 vs. 8.6 ± 0.8 fL, P = 0.016) and also higher than control group (9.2 ± 0.8 vs. 8.1 ± 0.9 fL, P < 0.001). Furthermore, patients who were not using antipsychotics had higher MPV than control group (8.6 ± 0.8 vs. 8.1 ± 0.9 fL, P = 0.036). Atypical antipsychotic use [Odds ratio (OR) =6.152, 95% confidence interval (CI,) P = 0.003)] and platelet distribution width (OR = 0.989, 95% CI, P = 0.032) were associated with high MPV levels in univariate analysis. In multivariate logistic regression model, only atypical antipsychotics use (OR = 6.152, 95% CI, P = 0.003) was found to be independent predictor of high MPV levels after adjustment of other potential confounders (age, gender, presence of hypertension, diabetes mellitus, hyperlipidemia, and smoking).


MPV seems to be influenced not only by schizophrenia itself but also by atypical antipsychotic drugs. It might be concluded that schizophrenic patients are under increased risk for cardiometabolic diseases and risk factors and this risk is higher in patients on atypical antipsychotic treatment.

Keywords: Atypical antipsychotics, cardiovascular disease, mean platelet volume, schizophrenia


Cardiovascular diseases are more frequently encountered in schizophrenic patients when compared with the general population.[1,2] Cardiovascular risk factors such as diabetes, obesity, and smoking are more common among schizophrenic patients when compared with healthy controls, so the risk for cardiovascular diseases is higher in schizophrenic patients.[3] Also, the mortality rate due to cardiovascular diseases is higher among schizophrenic patients when compared with the general population, and is frequently observed at younger ages. Furthermore, this mortality rate increases by time.[4] One of the explanations for the increased cardiovascular events in schizophrenic patients is increased platelet activity.[5]

It has been shown that platelet size, measured as mean platelet volume (MPV), correlates with their reactivity.[6] There is an increasing interest on MPV as an independent risk factor of atherosclerotic disease. Several studies have documented its association with acute myocardial infarction[7] and its prognosis,[8] with coronary atherosclerosis,[9] the presence and the short-term prognosis of stroke, and the long-term risk of stroke.[10] MPV measurement has now become a routine procedure in many laboratories, and its value is increasingly reported among the standard parameters of the whole blood count. High MPV levels have been reported in patients with hypertension,[11] hypercholesterolemia,[12] and a history of smoking.[13]

The primary objective of the present study was to investigate the relationship among the cardiovascular risk factors and the MPV levels in patients with schizophrenia using atypical antipsychotic drugs or not, along with comparison to healthy controls with regard to accompanying risk factors for cardiovascular disease.


Study population

This is a retrospective chart review study of Patients who were diagnosed with schizophrenia by a trained psychiatrist according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)[14] criteria of the American Psychiatric Association and hospitalized at the psychiatry clinic. Patients hospitalized between January 2008 and January 2010 were overviewed based on the hospital records. The patients who had alcohol and substance use disorders and who were diagnosed with co-morbid psychiatric disease were excluded from the study. Moreover, schizophrenic patients who were administered anti-depressant drugs, benzodiazepines, or mood stabilizers within the last month, patients who had known coronary artery disease and severe hepatic or renal failure, myelodysplastic syndrome, and patients who were taking anti-platelet and anti-coagulant drugs were also excluded from the study. The age- and sex-matched control group consisted of subjects who were similar to the population in terms of cardiovascular risk factors and had neither psychiatric nor cardiovascular diseases. So, 60 patients with schizophrenia and 30 controls were included in the present study. The patients with schizophrenia were also evaluated as two groups according to the presence or absence of antipsychotic drug use. Study was approved by local ethical committee. Informed consent was taken from all of the participants.

Data collection

The data of the consecutive patients who were hospitalized in the Department of Psychiatry of Sivas Cumhuriyet University, Faculty of Medicine between January 2008 and January 2010 were collected from the hospital records. Else, the present status of the patients was assessed by telephone call. The data regarding age, gender, duration of disease, use of psychiatric medications, presence of hypertension, diabetes mellitus, and hyperlipidemia, and smoking status were obtained from detailed history taken during admission to the psychiatry clinic.

Complete blood counts were determined by the samples which were drawn into vacutainer tubes containing 0.04 ml of the 7.5% K3 salt of ethylenediaminetetraacetic acid (EDTA) within 10-15 min and then analyzed by a Beckman-Coulter Gen-S Hemotology Analyzer.

Statistical analysis

Continuous variables were expressed as mean ± SD or median (min-max) in the presence of abnormal distribution, and categorical variables as percentages. Comparisons between groups of patients were made by use of a χ2 test for categorical variables, an independent samples t test for normally distributed continuous variables, and a Mann-Whitney U test when the distribution was skewed. Multiple logistic regression analysis was used to evaluate independent parameters affecting high MPV levels. Statistical procedures were performed using SPSS software version 15.0 (SPSS Inc., Chicago, IL). A P < 0.05 was considered significant.


Mean platelet volume levels were significantly higher in patients who were on atypical antipsychotic drugs than in patients who were not using any drug (9.2 ± 0.8 vs. 8.6 ± 0.8 fL, P = 0.016) and also higher than control group (9.2 ± 0.8 vs. 8.1 ± 0.9 fL, P < 0.001). Furthermore, patients who were not using antipsychotics had higher MPV than control group (8.6 ± 0.8 vs. 8.1 ± 0.9 fL, P = 0.036) [Figure 1].

Figure 1
Comparison of mean platelet volume levels between three groups

MPV levels were classified into two groups as those with relatively lower to normal (<8.5 fL) and those with higher (≥8.5 fL) according to analysis obtained from ROC curves (best sensitivity) and previous trials which indicated the level of MPV for outcomes.[15,16,17] Significant difference with respect to atypical antipsychotic drug usage was observed among the two groups classified according to MPV levels (6 [30%] vs. 29 [73%], P = 0.002, Table 1).

Table 1
Properties of the schizophrenia patients based on their mean platelet volume levels

Results of the univariate and multivariate analysis for determining high MPV levels are listed in Table 2. Atypical antipsychotic drug usage and platelet counts were found to have prognostic significance in univariate analysis. In multivariate logistic regression model with forward stepwise method, only atypical antipsychotic drug usage (OR: 6.152, P: 0.003, 95.0% CI: 1.887-20.053) was found to be an independent factor in determining high MPV levels in schizophrenic patients after adjustment for variables and were found to be statistically significant in univariate analysis and other potential confounders (age, gender, presence of hypertension, diabetes mellitus, hyperlipidemia, and smoking).

Table 2
Univariate and multivariate analyses of high mean platelet volume level (MPV ≥ 8.5 fL)


In the present study, MPV levels were significantly higher among patients with schizophrenia when compared with the healthy controls. In the schizophrenia group, it was also shown that atypical antipsychotic drug usage was an independent predictor for increased MPV levels.

Several factors such as genetic vulnerability,[18] illness-related outcomes,[19] unhealthy lifestyle choices,[20] and antipsychotic treatment,[21,22,23] are accused of increasing cardiometabolic risk factors in schizophrenia. Change in platelet activity has also been reported to contribute to increased cardiovascular disease and metabolic syndrome in patients with schizophrenia.[5] The platelets are considered to be a peripheral marker in major psychiatric diseases including schizophrenia.[24] In the in vitro study by Dietrich-Muszalska and Olas,[25] aggregation of blood platelets induced by ADP was found to be higher in schizophrenia patients than in healthy individuals. The findings of our study support the previous literature showing that patients with schizophrenia exhibit increased platelet activation. We believe we are the first to use MPV as an indicator of platelet activity in patients with schizophrenia.

Platelet function has a significant role in the development of atherothrombotic events that result in cardiovascular outcomes. MPV is an useful test that is easily obtained during routine clinical practice.[15] Platelets are heterogeneous cells in terms of size and density. MPV measurement is the most frequently used test to measure the size of platelets and it acts as a potential marker of platelet reactivity. An increase in MPV is associated with other parameters that indicate the platelet activity (e.g., platelet aggregation, increased thromboxane synthesis and b-thromboglobulin release, and increased expression of adhesion molecules).[15] MPV is an inexpensive and easy-to-interpret and -measure test carried out via automated cell counters, thus the measurement of MPV is ideal for routine clinical use.

MPV has been reported to be a determinant of platelet function. It has been previously reported that larger platelets have a greater mass, denser granules,[26] and are more active enzymatically and metabolically[27] than smaller platelets. They have a greater thrombotic potential caused by higher levels of intracellular thromboxane A2 and also express more procoagulant surface proteins such as P Selectin and Gp IIb/IIIa.[28] Additionally, larger platelets aggregate more rapidly than smaller platelets.[27] Increases in platelet volume are often associated with decreases in platelet count perhaps as a result of small platelets being consumed to maintain a constant platelet functional mass.[29] Concordant with this finding in our study, we found platelet count to be negatively and significantly related with MPV.

Increased MPV was shown to be associated with current (1 month) diagnosis of major depression in a large community-based population (n = 2286), even after excluding the subjects with risk factors capable of influencing platelet activity.[30] Also, in a clinical setting, MPV was found to be elevated in patients with major depression (11 women, 4 men) when compared with healthy individuals. Moreover, normalization of MPV levels was observed after 8 weeks treatment of escitalopram.[31] In the present study, we found that patients with schizophrenia exhibited elevated levels of MPV in comparison with healthy individuals as well.

Antipsychotic drugs are widely used in the treatment of psychotic disorders. Atypical antipsychotics are known to induce weight gain as well as cardiovascular and metabolic abnormalities, thereby increasing the patient's risk of obesity, the metabolic syndrome, type 2 diabetes mellitus and associated cardiovascular morbidity.[32] Increased risk of thrombotic events in schizophrenic patients treated with antipsychotic drugs have also been reported.[33,34,35] The antipsychotic treatment may cause the modification of platelet reactivity in vivo and in vitro.[36,37] The antiplatelet effects of antipsychotics have been established.[33,38]

The mechanisms explaining the relation between antipsychotics and blood platelet responses are not clear. Antipsychotics can alter platelet membrane lipid, receptors on the surface, intracellular messengers, or signal transduction. They may have some effects on platelet membrane structure and dynamics via lipid peroxidation caused by free radicals.[38,39] In the present study, we have found that atypical antipsychotics may affect blood platelet structure, namely, increase its volume. This finding may contribute to the explanation of the association of atypical antipsychotics with platelet activity.


The relatively small size of the population resulting in the lower number of variables for the log regression model was one of the limitations for our study. Typical and atypical antipsychotics are shown to exhibit different cardiovascular and metabolic side effects.[21,40] Unfortunately, in our study, the patients who were on medication consisted of patients using solely atypical antipsychotics. Therefore, we could not compare the effects of typical and atypical antipsychotics on MPV. Additionally, the severity of psychotic symptoms was not measured with an instrument such as Positive and Negative Syndrome Scale. Thus, the correlation of psychotic symptom severity with MPV levels could not be performed. Also, there was no control over the time lag between collection of sample and analysis, as it is a retrospective study. Nevertheless, this paper was aimed to provide initial data on the association of MPV levels with increased cardiac mortality and risk factors in patients with schizophrenia, especially in the ones on the atypical antipsychotic drugs and promoted large-scale studies in a controlled, prospective design.


To our awareness, the present study was the first to evaluate the MPV levels as well as its association with other cardiovascular risk factors in patients with schizophrenia, whether they were on atypical antipsychotics or not, and compared with the healthy controls. The data presented here demonstrate that MPV, which is associated with platelet activity, is higher in patients with schizophrenia than in healthy volunteers. The results of this study also indicate that atypical antipsychotics, which are commonplace in the treatment of schizophrenia, might cause an increase in the size of platelets in patients with schizophrenia. According to these results, it can be concluded that schizophrenic patients using atypical antipsychotic drugs should be monitored more closely and carefully regarding cardiovascular risk factors and MPV levels.


Source of Support: Nil

Conflict of Interest: None declared.


1. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: A review of the literature. Acta Psychiatr Scand. 2007;116:317–33. [PubMed]
2. Oud MJ, Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: Their prevalence and health care. BMC Fam Pract. 2009;10:32. [PMC free article] [PubMed]
3. Himelhoch S, Leith J, Goldberg R, Kreyenbuhl J, Medoff D, Dixon L. Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smoke. Gen Hosp Psychiatry. 2009;31:30–2. [PMC free article] [PubMed]
4. Haupt DW. Impact of medical comorbidity on medication management of schizophrenia. CNS Spectr. 2007;12:15–7. [PubMed]
5. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Sci. 2002;71:239–57. [PubMed]
6. Yetkin E. Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb Haemost. 2008;100:3–4. [PubMed]
7. Cameron HA, Phillips R, Ibbotson RM, Carson PH. Platelet size in myocardial infarction. Br Med J (Clin Res Ed) 1983;287:449–51. [PMC free article] [PubMed]
8. Kiliçli-Camur N, Demirtunç R, Konuralp C, Eskiser A, Başaran Y. Could mean platelet volume be a predictive marker for acute myocardial infarction? Med Sci Monit. 2005;11:CR387–92. [PubMed]
9. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409–11. [PubMed]
10. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke. 2004;35:1688–91. [PubMed]
11. Ordu S, Ozhan H, Caglar O, Alemdar R, Basar C, Yazici M, et al. Mean platelet volume in patients with dipper and non-dipper hypertension. Blood Press. 2010;19:26–30. [PubMed]
12. Pathansali R, Smith N, Bath P. Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets. 2001;12:292–7. [PubMed]
13. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol. 1992;14:281–7. [PubMed]
14. 4th ed. American Psychiatric Association; 1994. American Psychiatric Association. ???. 2000 American Psychiatric Association DSM-IV, Diagnostic and Statistical Manual of Mental Disorders. ???. p. ???
15. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: A systematic review and meta-analysis. J Thromb Haemost. 2010;8:148–56. [PMC free article] [PubMed]
16. Pizzulli L, Yang A, Martin JF, Lüderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J. 1998;19:80–4. [PubMed]
17. Yilmaz MB, Saricam E, Biyikoglu SF, Guray Y, Guray U, Sasmaz H, et al. Mean platelet volume and exercise stress test. J Thromb Thrombolysis. 2004;17:115–20. [PubMed]
18. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010;121:193–8. [PubMed]
19. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: A register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68:899–907. [PubMed]
20. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 2010;119:101–9. [PubMed]
21. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res. 2008;101:295–303. [PubMed]
22. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10:209–16. [PubMed]
23. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152–63. [PubMed]
24. Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol Clin. 2001;16:229–236. [PubMed]
25. Dietrich-Muszalska A, Olas B. The changes of aggregability of blood platelets in schizophrenia. World J Biol Psychiatry. 2009;10:171–6. [PubMed]
26. Martin JF, Shaw T, Heggie J, Penington DG. Measurement of the density of human platelets and its relationship to volume. Br J Haematol. 1983;54:337–52. [PubMed]
27. Karpatkin S, Khan Q, Freedman M. Heterogeneity of platelet function. Correlation with platelet volume. Am J Med. 1978;64:542–6. [PubMed]
28. Kamath S, Blann AD, Lip GY. Platelet activation: Assessment and quantification. Eur Heart J. 2001;22:1561–71. [PubMed]
29. Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood. 1988;72:1–8. [PubMed]
30. Canan F, Dikici S, Kutlucan A, Celbek G, Coskun H, Gungor A, et al. Association of mean platelet volume with DSM-IV major depression in a large community-based population: The MELEN study. J Psychiatr Res. 2012;46:298–302. [PubMed]
31. Ataoglu A, Canan F. Mean platelet volume in patients with major depression: Effect of escitalopram treatment. J Clin Psychopharmacol. 2009;29:368–71. [PubMed]
32. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114–26. [PubMed]
33. De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther. 2004;26:1261–73. [PubMed]
34. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry. 2001;179:63–6. [PubMed]
35. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: A case-control study. Lancet. 2000;356:1219–23. [PubMed]
36. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3:64–75. [PubMed]
37. Yao JK, van Kammen DP, Moss HB, Sokulski DE. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. Psychiatry Res. 1996;63:123–32. [PubMed]
38. Dietrich-Muszalska A. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psych Psychol Klin. 2004;4:215–23.
39. Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2004;71:171–6. [PubMed]
40. Nasrallah HA. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: Practical implications of the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68:5–11. [PubMed]

Articles from Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences are provided here courtesy of Medknow Publications